Selected article for: "candidate vaccine and vaccine candidate"

Author: Neha Jain; Uma Shankar; Prativa Majee; Amit Kumar
Title: Scrutinizing the SARS-CoV-2 protein information for the designing an effective vaccine encompassing both the T-cell and B-cell epitopes
  • Document date: 2020_4_1
  • ID: lmstdmyb_3
    Snippet: With the continuous transmission of the virus across borders and increasing health burden on the global scale, SARS-CoV-2 demands an urgent immunization therapy. As depicted by Shan Lu, the Community Acquired Coronavirus Infection (CACI) caused by this virus can shatter the socio-economic condition worldwide and the development of vaccine against the SARS-CoV-2 should be encouraged to manage the present situation as well as it can serve as a prot.....
    Document: With the continuous transmission of the virus across borders and increasing health burden on the global scale, SARS-CoV-2 demands an urgent immunization therapy. As depicted by Shan Lu, the Community Acquired Coronavirus Infection (CACI) caused by this virus can shatter the socio-economic condition worldwide and the development of vaccine against the SARS-CoV-2 should be encouraged to manage the present situation as well as it can serve as a prototype for other coronaviruses [30, 31] . Thereby, our analysis provides a platform for the development of a protective vaccine candidate that can be tested in-vitro and in-vivo and may lead to faster development of an efficient vaccine against the SARS-CoV-2 infection.

    Search related documents:
    Co phrase search for related documents
    • continuous transmission and SARS infection: 1, 2, 3, 4, 5
    • efficient vaccine and fast development: 1, 2
    • efficient vaccine and global scale: 1, 2, 3, 4
    • efficient vaccine and health burden: 1
    • efficient vaccine and present situation: 1
    • efficient vaccine and SARS infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • efficient vaccine and SARS infection efficient vaccine: 1
    • efficient vaccine and SARS vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • efficient vaccine and SARS vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • fast development and health burden: 1, 2, 3, 4, 5
    • fast development and SARS infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • fast development and SARS vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • fast development and SARS vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • global scale and health burden: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • global scale and SARS infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • global scale and SARS vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • global scale and SARS vaccine development: 1
    • health burden and SARS vaccine development: 1, 2, 3
    • health burden and socio economic condition: 1